FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:BCL2L11-BRAF

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: BCL2L11-BRAF
FusionPDB ID: 9342
FusionGDB2.0 ID: 9342
HgeneTgene
Gene symbol

BCL2L11

BRAF

Gene ID

10018

673

Gene nameBCL2 like 11B-Raf proto-oncogene, serine/threonine kinase
SynonymsBAM|BIM|BODB-RAF1|B-raf|BRAF1|NS7|RAFB1
Cytomap

2q13

7q34

Type of geneprotein-codingprotein-coding
Descriptionbcl-2-like protein 11BCL2-like 11 (apoptosis facilitator)bcl-2 interacting mediator of cell deathbcl-2 interacting protein Bimbcl-2-related ovarian death agonistserine/threonine-protein kinase B-raf94 kDa B-raf proteinB-Raf proto-oncogene serine/threonine-protein kinase (p94)B-Raf serine/threonine-proteinmurine sarcoma viral (v-raf) oncogene homolog B1proto-oncogene B-Rafv-raf murine sarcoma viral oncogene
Modification date2020031320200329
UniProtAcc

O43521

Main function of 5'-partner protein: FUNCTION: Induces apoptosis and anoikis. Isoform BimL is more potent than isoform BimEL. Isoform Bim-alpha1, isoform Bim-alpha2 and isoform Bim-alpha3 induce apoptosis, although less potent than isoform BimEL, isoform BimL and isoform BimS. Isoform Bim-gamma induces apoptosis. Isoform Bim-alpha3 induces apoptosis possibly through a caspase-mediated pathway. Isoform BimAC and isoform BimABC lack the ability to induce apoptosis. {ECO:0000269|PubMed:11997495, ECO:0000269|PubMed:15486195, ECO:0000269|PubMed:9430630}.

P15056

Main function of 5'-partner protein: FUNCTION: Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000305}.
Ensembl transtripts involved in fusion geneENST idsENST00000308659, ENST00000337565, 
ENST00000357757, ENST00000393253, 
ENST00000393256, ENST00000405953, 
ENST00000288602, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score7 X 4 X 6=16848 X 58 X 16=44544
# samples 969
** MAII scorelog2(9/168*10)=-0.900464326449086
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(69/44544*10)=-6.0124909441832
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: BCL2L11 [Title/Abstract] AND BRAF [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: BCL2L11 [Title/Abstract] AND BRAF [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)BCL2L11(111881716)-BRAF(140482957), # samples:3
Anticipated loss of major functional domain due to fusion event.BCL2L11-BRAF seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BCL2L11-BRAF seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BCL2L11-BRAF seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BCL2L11-BRAF seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneBCL2L11

GO:0008630

intrinsic apoptotic signaling pathway in response to DNA damage

11546872

HgeneBCL2L11

GO:0031334

positive regulation of protein complex assembly

21041309

HgeneBCL2L11

GO:0034976

response to endoplasmic reticulum stress

22761832

HgeneBCL2L11

GO:2000271

positive regulation of fibroblast apoptotic process

11997495

TgeneBRAF

GO:0000186

activation of MAPKK activity

29433126

TgeneBRAF

GO:0006468

protein phosphorylation

17563371

TgeneBRAF

GO:0010828

positive regulation of glucose transmembrane transport

23010278

TgeneBRAF

GO:0033138

positive regulation of peptidyl-serine phosphorylation

19667065

TgeneBRAF

GO:0043066

negative regulation of apoptotic process

19667065

TgeneBRAF

GO:0070374

positive regulation of ERK1 and ERK2 cascade

22065586

TgeneBRAF

GO:0071277

cellular response to calcium ion

18567582

TgeneBRAF

GO:0090150

establishment of protein localization to membrane

23010278



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:111881716/chr7:140482957)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across BCL2L11 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across BRAF (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000337565BCL2L11chr2111881716+ENST00000288602BRAFchr7140482957-17445021261625499
ENST00000357757BCL2L11chr2111881716+ENST00000288602BRAFchr7140482957-19246821261805559
ENST00000308659BCL2L11chr2111881716+ENST00000288602BRAFchr7140482957-17445021261625499
ENST00000393256BCL2L11chr2111881716+ENST00000288602BRAFchr7140482957-19096671111790559
ENST00000405953BCL2L11chr2111881716+ENST00000288602BRAFchr7140482957-145621401337445
ENST00000337565BCL2L11chr2111881446+ENST00000288602BRAFchr7140482957-16544121261535469
ENST00000393253BCL2L11chr2111881446+ENST00000288602BRAFchr7140482957-16544121261535469
ENST00000357757BCL2L11chr2111881446+ENST00000288602BRAFchr7140482957-17875453401668442
ENST00000308659BCL2L11chr2111881446+ENST00000288602BRAFchr7140482957-16544121261535469
ENST00000393256BCL2L11chr2111881446+ENST00000288602BRAFchr7140482957-17725303251653442
ENST00000405953BCL2L11chr2111881446+ENST00000288602BRAFchr7140482957-136612401247415

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000337565ENST00000288602BCL2L11chr2111881716+BRAFchr7140482957-0.0133077930.98669213
ENST00000357757ENST00000288602BCL2L11chr2111881716+BRAFchr7140482957-0.0147166620.9852834
ENST00000308659ENST00000288602BCL2L11chr2111881716+BRAFchr7140482957-0.0133077930.98669213
ENST00000393256ENST00000288602BCL2L11chr2111881716+BRAFchr7140482957-0.0140699750.98593
ENST00000405953ENST00000288602BCL2L11chr2111881716+BRAFchr7140482957-0.0078458040.9921542
ENST00000337565ENST00000288602BCL2L11chr2111881446+BRAFchr7140482957-0.0061787140.99382126
ENST00000393253ENST00000288602BCL2L11chr2111881446+BRAFchr7140482957-0.0061787140.99382126
ENST00000357757ENST00000288602BCL2L11chr2111881446+BRAFchr7140482957-0.0032362620.9967637
ENST00000308659ENST00000288602BCL2L11chr2111881446+BRAFchr7140482957-0.0061787140.99382126
ENST00000393256ENST00000288602BCL2L11chr2111881446+BRAFchr7140482957-0.003082010.99691796
ENST00000405953ENST00000288602BCL2L11chr2111881446+BRAFchr7140482957-0.0028355310.9971644

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for BCL2L11-BRAF

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
BCL2L11chr2111881446BRAFchr714048295712441RPGAPTSLQTEPQGSTTGLSATPPAS
BCL2L11chr2111881446BRAFchr714048295741295RPGAPTSLQTEPQGSTTGLSATPPAS
BCL2L11chr2111881446BRAFchr714048295753068PPCQAFNHYLSAMGSTTGLSATPPAS
BCL2L11chr2111881446BRAFchr714048295754568PPCQAFNHYLSAMGSTTGLSATPPAS
BCL2L11chr2111881716BRAFchr714048295721471PPCQAFNHYLSAMGSTTGLSATPPAS
BCL2L11chr2111881716BRAFchr7140482957502125PPCQAFNHYLSAMGSTTGLSATPPAS
BCL2L11chr2111881716BRAFchr7140482957667185PPCQAFNHYLSAMGSTTGLSATPPAS
BCL2L11chr2111881716BRAFchr7140482957682185PPCQAFNHYLSAMGSTTGLSATPPAS

Top

Potential FusionNeoAntigen Information of BCL2L11-BRAF in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
BCL2L11-BRAF_111881446_140482957.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B39:06NHYLSAMGS0.96450.7372615
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B35:03SAMGSTTGL0.90790.93031019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B35:08EPQGSTTGL0.82510.6321019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B07:10SAMGSTTGL0.81850.53161019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B46:01SAMGSTTGL0.7940.62531019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B35:02SAMGSTTGL0.79280.98731019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B35:04SAMGSTTGL0.79280.98731019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B35:03EPQGSTTGL0.74760.67731019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B35:02EPQGSTTGL0.52080.81781019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B35:04EPQGSTTGL0.52080.81781019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B81:01SAMGSTTGL0.46240.74351019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B81:01TEPQGSTTGL0.84380.6105919
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B82:01TEPQGSTTGL0.57280.5471919
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B07:05TEPQGSTTGL0.54730.5112919
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:22YLSAMGSTTGL0.9870.7641819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:24YLSAMGSTTGL0.95730.7315819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:67YLSAMGSTTGL0.95730.7315819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:30YLSAMGSTTGL0.95730.7315819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:13YLSAMGSTTGL0.95490.8862819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:11YLSAMGSTTGL0.95060.7626819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:27YLSAMGSTTGL0.94820.8051819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:16YLSAMGSTTGL0.93370.6422819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:29YLSAMGSTTGL0.90590.7351819
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B07:05QTEPQGSTTGL0.89670.527819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:38YLSAMGSTTGL0.89570.8545819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:17YLSAMGSTTGL0.88420.8179819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:19YLSAMGSTTGL0.880.7204819
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B82:01QTEPQGSTTGL0.72040.7437819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:19SAMGSTTGL0.99910.9911019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:07SAMGSTTGL0.99910.9671019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:08SAMGSTTGL0.99870.86221019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C15:06SAMGSTTGL0.99820.9741019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C04:06SAMGSTTGL0.99160.97881019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C06:03SAMGSTTGL0.98340.99721019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C12:04SAMGSTTGL0.98260.99771019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C12:12SAMGSTTGL0.98120.96311019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C08:13SAMGSTTGL0.98080.98631019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C08:04SAMGSTTGL0.98080.98631019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C02:06SAMGSTTGL0.94090.98341019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C08:03SAMGSTTGL0.91820.99411019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:14SAMGSTTGL0.81880.99141019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B35:12SAMGSTTGL0.79280.98731019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B07:12SAMGSTTGL0.74630.66871019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C01:30SAMGSTTGL0.56070.98161019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C01:17SAMGSTTGL0.54720.98061019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B35:12EPQGSTTGL0.52080.81781019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B39:10EPQGSTTGL0.31130.84831019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B42:02EPQGSTTGL0.28780.69931019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B42:01EPQGSTTGL0.2190.69041019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B39:08TEPQGSTTGL0.8330.8134919
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B07:12TEPQGSTTGL0.64690.5385919
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B39:10TEPQGSTTGL0.63380.8423919
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B42:01TEPQGSTTGL0.46110.7445919
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:02YLSAMGSTTGL0.98870.691819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A02:01YLSAMGSTTGL0.95730.7315819
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B07:12QTEPQGSTTGL0.93490.5032819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:04SAMGSTTGL0.99920.98611019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:03SAMGSTTGL0.99920.98611019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:67SAMGSTTGL0.99850.97561019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:05SAMGSTTGL0.9980.9271019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:17SAMGSTTGL0.9980.9851019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C15:02SAMGSTTGL0.99790.96781019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C15:05SAMGSTTGL0.99770.97581019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:02SAMGSTTGL0.99720.97981019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C16:04SAMGSTTGL0.99250.99111019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C12:03SAMGSTTGL0.98870.99221019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C12:02SAMGSTTGL0.9870.99071019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:06SAMGSTTGL0.98580.99311019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C08:01SAMGSTTGL0.91820.99411019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C02:02SAMGSTTGL0.91690.98781019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C02:10SAMGSTTGL0.91690.98781019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A68:02SAMGSTTGL0.91390.81391019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C16:02SAMGSTTGL0.89940.99591019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B35:13SAMGSTTGL0.89940.93491019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B07:13SAMGSTTGL0.89780.87981019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C16:01SAMGSTTGL0.88620.99031019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-A69:01SAMGSTTGL0.83390.79221019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B35:09SAMGSTTGL0.79280.98731019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C17:01SAMGSTTGL0.78030.98211019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B35:22SAMGSTTGL0.74420.63041019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-B15:30SAMGSTTGL0.70890.9531019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C01:02SAMGSTTGL0.60280.98031019
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C01:03SAMGSTTGL0.59040.96721019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B35:09EPQGSTTGL0.52080.81781019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B67:01EPQGSTTGL0.34250.79171019
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B40:49TEPQGSTTGL0.80210.5282919
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B67:01TEPQGSTTGL0.61380.8157919
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B82:02TEPQGSTTGL0.57280.5471919
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B41:03TEPQGSTTGL0.40440.6125919
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:04YLSAMGSTTGL0.98710.9954819
BCL2L11-BRAFchr2111881446chr7140482957545HLA-C03:03YLSAMGSTTGL0.98710.9954819
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B67:01QTEPQGSTTGL0.75370.8292819
BCL2L11-BRAFchr2111881446chr7140482957412HLA-B82:02QTEPQGSTTGL0.72040.7437819

Top

Potential FusionNeoAntigen Information of BCL2L11-BRAF in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of BCL2L11-BRAF

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6189NHYLSAMGSTTGLSBCL2L11BRAFchr2111881446chr7140482957545
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
8780SLQTEPQGSTTGLSBCL2L11BRAFchr2111881446chr7140482957412

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of BCL2L11-BRAF

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6189NHYLSAMGSTTGLS-7.15543-7.26883
HLA-B14:023BVN6189NHYLSAMGSTTGLS-4.77435-5.80965
HLA-B52:013W396189NHYLSAMGSTTGLS-6.80875-6.92215
HLA-B52:013W396189NHYLSAMGSTTGLS-4.20386-5.23916
HLA-A11:014UQ26189NHYLSAMGSTTGLS-7.5194-8.5547
HLA-A11:014UQ26189NHYLSAMGSTTGLS-6.9601-7.0735
HLA-A24:025HGA6189NHYLSAMGSTTGLS-7.52403-7.63743
HLA-A24:025HGA6189NHYLSAMGSTTGLS-5.82433-6.85963
HLA-B27:056PYJ6189NHYLSAMGSTTGLS-3.28285-4.31815
HLA-B44:053DX86189NHYLSAMGSTTGLS-5.91172-6.94702
HLA-B44:053DX86189NHYLSAMGSTTGLS-4.24346-4.35686
HLA-B14:023BVN8780SLQTEPQGSTTGLS-7.15543-7.26883
HLA-B14:023BVN8780SLQTEPQGSTTGLS-4.77435-5.80965
HLA-B52:013W398780SLQTEPQGSTTGLS-6.80875-6.92215
HLA-B52:013W398780SLQTEPQGSTTGLS-4.20386-5.23916
HLA-A11:014UQ28780SLQTEPQGSTTGLS-7.5194-8.5547
HLA-A11:014UQ28780SLQTEPQGSTTGLS-6.9601-7.0735
HLA-A24:025HGA8780SLQTEPQGSTTGLS-7.52403-7.63743
HLA-A24:025HGA8780SLQTEPQGSTTGLS-5.82433-6.85963
HLA-B27:056PYJ8780SLQTEPQGSTTGLS-3.28285-4.31815
HLA-B44:053DX88780SLQTEPQGSTTGLS-5.91172-6.94702
HLA-B44:053DX88780SLQTEPQGSTTGLS-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of BCL2L11-BRAF

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
BCL2L11-BRAFchr2111881446chr71404829571019EPQGSTTGLAGCCACAAGGATCAACCACAGGTTTGT
BCL2L11-BRAFchr2111881446chr71404829571019SAMGSTTGLGTGCAATGGGATCAACCACAGGTTTGT
BCL2L11-BRAFchr2111881446chr7140482957615NHYLSAMGSACCACTATCTCAGTGCAATGGGATCAA
BCL2L11-BRAFchr2111881446chr7140482957819QTEPQGSTTGLAGACAGAGCCACAAGGATCAACCACAGGTTTGT
BCL2L11-BRAFchr2111881446chr7140482957819YLSAMGSTTGLATCTCAGTGCAATGGGATCAACCACAGGTTTGT
BCL2L11-BRAFchr2111881446chr7140482957919TEPQGSTTGLCAGAGCCACAAGGATCAACCACAGGTTTGT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of BCL2L11-BRAF

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
THCABCL2L11-BRAFchr2111881446ENST00000308659chr7140482957ENST00000288602TCGA-ET-A2MX-01A
THCABCL2L11-BRAFchr2111881446ENST00000357757chr7140482957ENST00000288602TCGA-ET-A2MX-01A

Top

Potential target of CAR-T therapy development for BCL2L11-BRAF

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to BCL2L11-BRAF

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to BCL2L11-BRAF

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
TgeneBRAFC0025202melanoma24CGI;CTD_human;UNIPROT
TgeneBRAFC1275081Cardio-facio-cutaneous syndrome14CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
TgeneBRAFC0009402Colorectal Carcinoma8CTD_human;UNIPROT
TgeneBRAFC0028326Noonan Syndrome8CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET
TgeneBRAFC0238463Papillary thyroid carcinoma8CTD_human;ORPHANET
TgeneBRAFC0040136Thyroid Neoplasm6CGI;CTD_human
TgeneBRAFC0151468Thyroid Gland Follicular Adenoma6CTD_human
TgeneBRAFC0175704LEOPARD Syndrome6CLINGEN;GENOMICS_ENGLAND
TgeneBRAFC0549473Thyroid carcinoma6CGI;CTD_human
TgeneBRAFC3150970NOONAN SYNDROME 75CTD_human;GENOMICS_ENGLAND;UNIPROT
TgeneBRAFC0009404Colorectal Neoplasms4CTD_human
TgeneBRAFC3150971LEOPARD SYNDROME 34CTD_human;GENOMICS_ENGLAND;UNIPROT
TgeneBRAFC1519086Pilomyxoid astrocytoma3ORPHANET
TgeneBRAFC0004565Melanoma, B162CTD_human
TgeneBRAFC0009075Melanoma, Cloudman S912CTD_human
TgeneBRAFC0018598Melanoma, Harding-Passey2CTD_human
TgeneBRAFC0023443Hairy Cell Leukemia2CGI;ORPHANET
TgeneBRAFC0025205Melanoma, Experimental2CTD_human
TgeneBRAFC0033578Prostatic Neoplasms2CTD_human
TgeneBRAFC0152013Adenocarcinoma of lung (disorder)2CGI;CTD_human
TgeneBRAFC0376358Malignant neoplasm of prostate2CTD_human
TgeneBRAFC0587248Costello syndrome (disorder)2CLINGEN;CTD_human
TgeneBRAFC3501843Nonmedullary Thyroid Carcinoma2CTD_human
TgeneBRAFC3501844Familial Nonmedullary Thyroid Cancer2CTD_human
TgeneBRAFC0002448Ameloblastoma1CTD_human
TgeneBRAFC0004114Astrocytoma1CTD_human
TgeneBRAFC0010276Craniopharyngioma1CTD_human;ORPHANET
TgeneBRAFC0011860Diabetes Mellitus, Non-Insulin-Dependent1CTD_human
TgeneBRAFC0017638Glioma1CGI;CTD_human
TgeneBRAFC0019621Histiocytosis, Langerhans-Cell1CGI;ORPHANET
TgeneBRAFC0022665Kidney Neoplasm1CTD_human
TgeneBRAFC0023903Liver neoplasms1CTD_human
TgeneBRAFC0024232Lymphatic Metastasis1CTD_human
TgeneBRAFC0024694Mandibular Neoplasms1CTD_human
TgeneBRAFC0027659Neoplasms, Experimental1CTD_human
TgeneBRAFC0027962Melanocytic nevus1GENOMICS_ENGLAND
TgeneBRAFC0036920Sezary Syndrome1CTD_human
TgeneBRAFC0041409Turner Syndrome, Male1CTD_human
TgeneBRAFC0079773Lymphoma, T-Cell, Cutaneous1CTD_human
TgeneBRAFC0205768Subependymal Giant Cell Astrocytoma1CTD_human
TgeneBRAFC0206686Adrenocortical carcinoma1CTD_human
TgeneBRAFC0206754Neuroendocrine Tumors1CTD_human
TgeneBRAFC0259783mixed gliomas1CTD_human
TgeneBRAFC0278875Adult Craniopharyngioma1CTD_human
TgeneBRAFC0280783Juvenile Pilocytic Astrocytoma1CTD_human
TgeneBRAFC0280785Diffuse Astrocytoma1CTD_human
TgeneBRAFC0334579Anaplastic astrocytoma1CGI;CTD_human
TgeneBRAFC0334580Protoplasmic astrocytoma1CTD_human
TgeneBRAFC0334581Gemistocytic astrocytoma1CTD_human
TgeneBRAFC0334582Fibrillary Astrocytoma1CTD_human
TgeneBRAFC0334583Pilocytic Astrocytoma1CGI;CTD_human
TgeneBRAFC0338070Childhood Cerebral Astrocytoma1CTD_human
TgeneBRAFC0345904Malignant neoplasm of liver1CTD_human
TgeneBRAFC0376407Granulomatous Slack Skin1CTD_human
TgeneBRAFC0406803Syringocystadenoma Papilliferum1GENOMICS_ENGLAND
TgeneBRAFC0431128Papillary craniopharyngioma1CTD_human
TgeneBRAFC0431129Adamantinous Craniopharyngioma1CTD_human
TgeneBRAFC0547065Mixed oligoastrocytoma1CTD_human
TgeneBRAFC0555198Malignant Glioma1CTD_human
TgeneBRAFC0596263Carcinogenesis1CTD_human
TgeneBRAFC0684249Carcinoma of lung1CGI;UNIPROT
TgeneBRAFC0740457Malignant neoplasm of kidney1CTD_human
TgeneBRAFC0750935Cerebral Astrocytoma1CTD_human
TgeneBRAFC0750936Intracranial Astrocytoma1CTD_human
TgeneBRAFC0751061Craniopharyngioma, Child1CTD_human
TgeneBRAFC0920269Microsatellite Instability1CTD_human
TgeneBRAFC1527404Female Pseudo-Turner Syndrome1CTD_human
TgeneBRAFC1704230Grade I Astrocytoma1CTD_human
TgeneBRAFC1721098Replication Error Phenotype1CTD_human
TgeneBRAFC2239176Liver carcinoma1CTD_human
TgeneBRAFC4551484Leopard Syndrome 11GENOMICS_ENGLAND
TgeneBRAFC4551602Noonan Syndrome 11CTD_human
TgeneBRAFC4721532Lymphoma, Non-Hodgkin, Familial1UNIPROT
TgeneBRAFC4733333familial non-medullary thyroid cancer1GENOMICS_ENGLAND